Dear John, I loved your trades this year! 10% plus in a day? I’ll take as many of those as you can dream up. And pulling this off in this boring market is incredible. After reading BS and extreme negativity in my other newsletters all day long, you are a breath of fresh air. Keep
When I visited the local fire station in the spring, I was snared by some uniformed pre-teens, backed by beaming mothers behind a card table selling Girl Scout cookies. I was a pushover. I walked away with a bag of Thin Mints, Lemon Chalet Creams, Do-Si-Dos, and Tagalongs. I have to confess a lifetime addiction
When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline.
Mad Hedge Biotech and Healthcare Letter April 30, 2024 Fiat Lux Featured Trade: (HITTING CTRL+ALT+DELETE ON DRUG R&D) (DNA), (GOOGL), (JNJ), (ILMN), (JNJ), (ALTO), (GROIV)
Forget your classic biotech launch story. One of 2024's most lavishly funded biotech upstarts is taking a massively ambitious swing at reinventing the entire drug development process. I'm talking AI, venture billions, and some serious star power all rolled into one wild capital extravaganza. The company behind this cash-flushed disruption bid is Xaira Therapeutics. And
Global Market Comments April 30, 2024 Fiat Lux Featured Trade: (MAY 8 GALAPAGOS ISLANDS STRATEGY LUNCHEON) SPECIAL AMAZON ISSUE (WHY I’M LOOKING AT AMAZON), (AMZN)
At the beginning of 2023, Amazon was universally despised. It shares having dropped by more than half during 2022, the company was believed to be hobbled by rising competition, an out-of-date business model, and an imminent antitrust suit. What a difference 16 months makes. I believe there is a good chance that this creation of
Mad Hedge Technology Letter April 29, 2024 Fiat Lux Featured Trade: (JUST GOOD ENOUGH) (META), (F), (IBM), (MSFT)
This earnings season is chugging along exactly like I thought it would play out. The haves are covering for the have-nots. Sadly, the pixie dust isn’t encompassing all tech stocks, but just enough sprinkles so investors don’t start selling. That is what matters most and sure, investors can knit-pick all they want, but there have
“The future doesn't belong to the fainthearted; it belongs to the brave.” – Said Former US President Ronald Reagan